ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males

Aging Male

Volumn 12, Issue 1, 2009, Pages 5-12

  Wang, Christina ^a   Nieschlag, Eberhard ^b   Swerdloff, Ronald S ^a   Behre, Hermann ^c   Hellstrom, Wayne J ^d   Gooren, Louis J ^e   Kaufman, Jean M ^f   Legros, Jean Jacques ^g   Lunenfeld, Bruno ^h   Morales, Alvaro ⁱ   Morley, John E ^j   Schulman, Claude ^k   Thompson, Ian M ^l   Weidner, Wolfgang ^m   Wu, Frederick C W ⁿ  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h BAR ILAN UNIVERSITY   (Israel)

ⁱ QUEEN S UNIVERSITY   (Canada)

^j SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ERASME HOSPITAL   (Belgium)

^l UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^m JUSTUS LIEBIG UNIVERSITY   (Germany)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LUTEINIZING HORMONE; PHOSPHODIESTERASE V INHIBITOR; TESTOSTERONE; ANDROGEN;

AGING; ANDROGEN DEFICIENCY; BODY COMPOSITION; BONE DENSITY; CLINICAL FEATURE; COMORBIDITY; DRUG CONTRAINDICATION; DRUG POTENTIATION; EQUILIBRIUM DIALYSIS; ERECTILE DYSFUNCTION; ERYTHROCYTOSIS; FRACTURE; HUMAN; HYPOGONADISM; LABORATORY TEST; LATE ONSET HYPOGONADISM; LIBIDO DISORDER; LUTEINIZING HORMONE BLOOD LEVEL; MEDICAL SOCIETY; MEN'S HEALTH; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUESTIONNAIRE; REVIEW; RISK FACTOR; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; ARTICLE; BLOOD; MALE; ONSET AGE; PROSTATE TUMOR;

AGE OF ONSET; ANDROGENS; BODY COMPOSITION; HUMANS; HYPOGONADISM; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 66149139494     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530802389628     Document Type: Review

References (88)

1. Araujo AB, Esche GR, Kupelian V, O'donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-4247.
2. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016-1025.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serumtotal and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-731.
4. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors. J Clin Endocrinol Metab 2008;93:2737-2745.
5. Liverman CT, Blazer DG. Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academies Press; 2004.
6. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol (Oxf) 2005;63:381-394.
7. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-293.
8. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89:503-510.
9. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005;90: 1502-1510.
10. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ, Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-2653. (Pubitemid 30641987)
11. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84: 1966-1972. (Pubitemid 30647018)
12. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
13. The Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. Fertil Steril 2004;81:1437-1440.
14. AACE Hypogonadism Task Force. American Association of Clinical Endocrinologist Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients - Update 2002. http://www.aace.com/ pub/pdf/guidelines/hypogonadism.pdf; 2002.
15. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002;5:74-86.
16. Nieschlag E, Swerdloff R, BehreHM, Gooren LJ,Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, WeidnerW,Wu FC. Investigation, treatment andmonitoring of late-onset hypogonadism in Males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005;48:1-4. (Pubitemid 40835584)
17. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005;8:56-58.
18. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005;28: 125-127. (Pubitemid 40780337)
19. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, WeidnerW,Wu FC. Investigation, treatment, andmonitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU Recommendations. J Androl 2006;27:135-137.
20. Morales A, Schulman CC, Tostain J, Wu CW. Testosterone Deficiency Syndrome (TDS) needs to be named appropriately - the importance of accurate terminology. Eur Urol 2006;50:407-409.
21. Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med 1991;53:363-374.
22. Travison TG, Morley JE, Araujo AB, O'donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006;91:2509-2513.
23. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89:3813-3817.
24. Morales A, Spevack M, Emerson L, Kuzmarov I, Casey R, Black A, Tremblay R. Adding to the controversy: Pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male 2007;10:57-65.
25. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-4343.
26. Heinemann LA, Saad F, Heinemann K, Thai DM. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency? Aging Male 2004;7:211-218. (Pubitemid 39315125)
27. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004;46:80-87. (Pubitemid 38748514)
28. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-1242.
29. Tancredi A, Reginster JY, Schleich F, Pire G, Maassen P, Luyckx F, Legros JJ. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004;151:355-360.
30. Beutel ME, Wiltink J, Hauck EW, Auch D, Behre HM, Brahler E, Weidner W. Correlations between hormones, physical, and affective parameters in aging urologic outpatients. Eur Urol 2005;47:749-755.
31. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003;58:710-717.
32. Citron JT, Ettinger B, Rubinoff H, Ettinger VM, Minkoff J, Hom F, Kan P, Alloo R. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996;155:529-533.
33. Bunch TJ, Abraham D, Wang S, Meikle AW. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male 2002;5:38-46.
34. Rhoden EL, Estrada C, Levine L, Morgentaler A. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol 2003;170:795-798.
35. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: Clinical significance and cost-effective strategy. J Urol 1997;158:1764-1767.
36. Araujo AB, O'Donnell A, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 2004;89:5920-5926.
37. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: A survey of androgen assays. J Endocrinol Invest 2005;28:28-31.
38. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society Position Statement. J Clin Endocrinol Metab 2007;92:405-413.
39. Sikaris K, McLachlan RI, Kazlauskas R, de KD, Holden CA, Handelsman DJ. Reproductive hormone reference intervals for healthy fertile young men: Evaluation of automated platform assays. J Clin Endocrinol Metab 2005;90:5928-5936.
40. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotopedilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49:1381-1395.
41. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: Comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:534-543.
42. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672.
43. Swerdloff RS, Wang C. Free testosterone measurement by the analog displacement direct assay: Old concerns and new evidence. Clin Chem 2008;54:458-460.
44. Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997;82:2014-2015.
45. Wang C, Plymate S, Nieschlag E, Paulsen CA. Salivary testosterone in men: Further evidence of a direct correlation with free serum testosterone. J Clin Endocrinol Metab 1981;53:1021-1024.
46. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008;93:139-146.
47. Meier C, Nguyen TV, Handelsman DJ, Schindler C, KushnirMM, Rockwood AL, Meikle AW, Center JR, Eisman JA, Seibel MJ. Endogenous sex hormones and incident fracture risk in older men: The Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008;168:47-54.
48. Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res 2000; 26:153-168.
49. Freitas SS, Barrett-Connor E, Ensrud KE, Fink HA, Bauer DC, Cawthon PM, Lambert LC, Orwoll ES. Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 2007;19:615-623.
50. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ III, Bauer DC, Ensrud KE. Costeffectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007;298:629-637.
51. Morales A, Buvat J, Gorren LJ, Guay AT, Kaufman JM, Tan HM, Torres LO. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004;1:69-81.
52. Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: Can a case be made for a 3-month therapeutic trial? BJU Int 2004;94:1066-1070.
53. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-663.
54. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005;173:530-532.
55. Allen NE, Appleby PN, Davey GK, Key TJ. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 2002;13: 353-363.
56. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14:226-234.
57. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA. Androgens and diabetes in men: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234-238. (Pubitemid 46198324)
58. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:3568-3572. (Pubitemid 47435336)
59. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: The Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006;65:125-131.
60. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30:911-917.
61. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006;91:843-850.
62. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-1041.
63. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
64. Corrales JJ, Burgo RM, Garca-Berrocal B, Almeida M, Alberca I, Gonzalez-Buitrago JM, Orfao A, Miralles JM. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004;53: 666-672.
65. Basu R, Dalla MC, Campioni M, Basu A, Nair KS, Jensen MD, Khosla S, Klee G, Toffolo G, Cobelli C, Rizza RA. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007;30:1972-1978. (Pubitemid 47219403)
66. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-183.
67. Carpenter WR, Robinson WR, Godley PA. Getting over testosterone: Postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst 2008;100:158-159.
68. Fowler JE Jr, Whitmore WF Jr. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 1982;49:1373-1377.
69. McConnell JD. Prostatic growth: New insights into hormonal regulation. Br J Urol 1995;76:5-10.
70. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby- Hagino E, Brand T, Troyer DA, Leach RJ, Thompson IM. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006;68: 1152-1155.
71. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98: 529-534. (Pubitemid 43898816)
72. Thompson IM, Carroll PR, Carducci MA. Recommendations for defining and treating high risk localized prostate cancer. J Urol 2006;176:S6-S10.
73. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: A randomized controlled trial. JAMA 2006; 296:2351-2361.
74. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, Rajaram L, Mazer NA. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997;49:191-196.
75. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan. J Androl 2003;24:299-311.
76. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-492.
77. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533-536.
78. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-922.
79. Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am 2007;34:549-553, vi.
80. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109:536-541.
81. Nieschlag E, Behre HM. Testosterone: Action, Deficiency, Substitution. 3rd edn. Cambridge: Cambridge University Press; 2004.
82. Nieschlag E. Testosterone treatment comes of age: New options for hypogonadal men. Clin Endocrinol (Oxf) 2006; 65:275-281.
83. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-1457.
84. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P,Metter EJ. Serum testosterone and the risk of prostate cancer: Potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14:2257-2260.
85. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007;92:3844-3853.
86. Malkin CJ, Pugh PJ, West JN, Van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006;27:57-64.
87. Hanafy HM. Testosterone therapy and obstructive sleep apnea: Is there a real connection? J Sex Med 2007;4:1241-1246.
88. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995;43:899-901.